These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 22521463)

  • 41. (18)F-FCWAY, a serotonin 1A receptor radioligand, is a substrate for efflux transport at the human blood-brain barrier.
    Liow JS; Zoghbi SS; Hu S; Hall MD; Hines CS; Shetty HU; Araneta MD; Page EM; Pike VW; Kreisl WC; Herscovitch P; Gottesman MM; Theodore WH; Innis RB
    Neuroimage; 2016 Sep; 138():134-140. PubMed ID: 27211474
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Neutral Lipid Cacostasis Contributes to Disease Pathogenesis in Amyotrophic Lateral Sclerosis.
    Dodge JC; Jensen EH; Yu J; Sardi SP; Bialas AR; Taksir TV; Bangari DS; Shihabuddin LS
    J Neurosci; 2020 Nov; 40(47):9137-9147. PubMed ID: 33051352
    [TBL] [Abstract][Full Text] [Related]  

  • 43. In vivo and ex vivo regulation of breast cancer resistant protein (Bcrp) by peroxisome proliferator-activated receptor alpha (Pparα) at the blood-brain barrier.
    Hoque MT; Shah A; More V; Miller DS; Bendayan R
    J Neurochem; 2015 Dec; 135(6):1113-22. PubMed ID: 26465636
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Regulation of ABC efflux transporters at blood-brain barrier in health and neurological disorders.
    Qosa H; Miller DS; Pasinelli P; Trotti D
    Brain Res; 2015 Dec; 1628(Pt B):298-316. PubMed ID: 26187753
    [TBL] [Abstract][Full Text] [Related]  

  • 45. N-desmethyl-loperamide is selective for P-glycoprotein among three ATP-binding cassette transporters at the blood-brain barrier.
    Kannan P; Brimacombe KR; Zoghbi SS; Liow JS; Morse C; Taku AK; Pike VW; Halldin C; Innis RB; Gottesman MM; Hall MD
    Drug Metab Dispos; 2010 Jun; 38(6):917-22. PubMed ID: 20212014
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Saturable active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier leads to nonlinear distribution of elacridar to the central nervous system.
    Sane R; Agarwal S; Mittapalli RK; Elmquist WF
    J Pharmacol Exp Ther; 2013 Apr; 345(1):111-24. PubMed ID: 23397054
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Toll-Like Receptor-4 Inhibitor TAK-242 Attenuates Motor Dysfunction and Spinal Cord Pathology in an Amyotrophic Lateral Sclerosis Mouse Model.
    Fellner A; Barhum Y; Angel A; Perets N; Steiner I; Offen D; Lev N
    Int J Mol Sci; 2017 Aug; 18(8):. PubMed ID: 28763002
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Expression and function of multidrug resistance transporters at the blood-brain barriers.
    Scherrmann JM
    Expert Opin Drug Metab Toxicol; 2005 Aug; 1(2):233-46. PubMed ID: 16922639
    [TBL] [Abstract][Full Text] [Related]  

  • 49. CNS uptake of bortezomib is enhanced by P-glycoprotein inhibition: implications for spinal muscular atrophy.
    Foran E; Kwon DY; Nofziger JH; Arnold ES; Hall MD; Fischbeck KH; Burnett BG
    Neurobiol Dis; 2016 Apr; 88():118-24. PubMed ID: 26792401
    [TBL] [Abstract][Full Text] [Related]  

  • 50. ABC transporters during epilepsy and mechanisms underlying multidrug resistance in refractory epilepsy.
    Lazarowski A; Czornyj L; Lubienieki F; Girardi E; Vazquez S; D'Giano C
    Epilepsia; 2007; 48 Suppl 5():140-9. PubMed ID: 17910594
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Induced expression of P-gp and BCRP transporters on brain endothelial cells using transferrin functionalized nanostructured lipid carriers: A first step of a potential strategy for the treatment of Alzheimer's disease.
    Arduino I; Iacobazzi RM; Riganti C; Lopedota AA; Perrone MG; Lopalco A; Cutrignelli A; Cantore M; Laquintana V; Franco M; Colabufo NA; Luurtsema G; Contino M; Denora N
    Int J Pharm; 2020 Dec; 591():120011. PubMed ID: 33115695
    [TBL] [Abstract][Full Text] [Related]  

  • 52. P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) localize in the microvessels forming the blood-tumor barrier in ependymomas.
    Ginguené C; Champier J; Maallem S; Strazielle N; Jouvet A; Fèvre-Montange M; Ghersi-Egea JF
    Brain Pathol; 2010 Sep; 20(5):926-35. PubMed ID: 20406235
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Dexamethasone increases expression and activity of multidrug resistance transporters at the rat blood-brain barrier.
    Narang VS; Fraga C; Kumar N; Shen J; Throm S; Stewart CF; Waters CM
    Am J Physiol Cell Physiol; 2008 Aug; 295(2):C440-50. PubMed ID: 18524938
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Novel understanding of ABC transporters ABCB1/MDR/P-glycoprotein, ABCC2/MRP2, and ABCG2/BCRP in colorectal pathophysiology.
    Andersen V; Svenningsen K; Knudsen LA; Hansen AK; Holmskov U; Stensballe A; Vogel U
    World J Gastroenterol; 2015 Nov; 21(41):11862-76. PubMed ID: 26557010
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on the brain distribution of a novel BRAF inhibitor: vemurafenib (PLX4032).
    Mittapalli RK; Vaidhyanathan S; Sane R; Elmquist WF
    J Pharmacol Exp Ther; 2012 Jul; 342(1):33-40. PubMed ID: 22454535
    [TBL] [Abstract][Full Text] [Related]  

  • 56. In vitro modulation of P-glycoprotein, MRP-1 and BCRP expression by mangiferin in doxorubicin-treated MCF-7 cells.
    Louisa M; Soediro TM; Suyatna FD
    Asian Pac J Cancer Prev; 2014; 15(4):1639-42. PubMed ID: 24641381
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A combo-strategy to improve brain delivery of antiepileptic drugs: Focus on BCRP and intranasal administration.
    Gonçalves J; Silva S; Gouveia F; Bicker J; Falcão A; Alves G; Fortuna A
    Int J Pharm; 2021 Jan; 593():120161. PubMed ID: 33307160
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Blood-brain barrier active efflux transporters: ATP-binding cassette gene family.
    Löscher W; Potschka H
    NeuroRx; 2005 Jan; 2(1):86-98. PubMed ID: 15717060
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The accumulation of enzymatically inactive cuproenzymes is a CNS-specific phenomenon of the SOD1
    Hilton JB; Kysenius K; White AR; Crouch PJ
    Exp Neurol; 2018 Sep; 307():118-128. PubMed ID: 29906423
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Identification of novel specific and general inhibitors of the three major human ATP-binding cassette transporters P-gp, BCRP and MRP2 among registered drugs.
    Matsson P; Pedersen JM; Norinder U; Bergström CA; Artursson P
    Pharm Res; 2009 Aug; 26(8):1816-31. PubMed ID: 19421845
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.